Chongqing Tianwaitian Biotechnology, a wholly owned subsidiary of SWS, recently received the change registration filing document for the continuous blood purification tubing medical device from the National Medical Products Administration. The product registration certificate is valid from December 30, 2022 to December 29, 2027. In the first quarter of 2026, SWS achieved revenue of 230 million yuan and net profit attributable to the parent company of 54.48 million yuan.
SWS Hemodialysis Care Co. Ltd. ASubsidiary obtained regulatory change registration for continuous blood purification tubing, extending product validity to 2027.
